arrow
D

David G. Silverman

johns-hopkins university
H指数:46
被引数:6,238

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Severe maternal morbidity contributed by obstetric hemorrhage: Maryland, 2020-2022

产科出血导致严重的孕产妇发病率: 马里兰州,2020-2022

2025-02-010
PRE
Two-Year Results from the Phase 3 Neovascular Age- Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

Faricimab治疗和延长给药2年的3期新生血管性年龄相关性黄斑变性试验的两年结果

2024-08-0124
OA
Faricimab Treat-and-Extend for Diabetic Macular Edema
2024-06-0126
OA
Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials
2023-09-016
OAAI
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

玻璃体内注射faricimab每16周治疗新生血管性年龄相关性黄斑变性 (TENAYA和LUCERNE) 的疗效、持久性和安全性: 两项随机、双盲、3期非劣效性试验

LANCET
IF88.5
2022-02-01294
OAAI
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
LANCET
IF88.5
2022-02-01213
OAAI